Drug intelligence / Profile preview

donor-derived SARS-CoV-2-specific T cells

Development stage: Unknown
Lead developer: City of Hope
Modality: Cell Therapies
Administration: Intravenous

Overview

Donor-derived SARS-CoV-2-specific T cells (CST) are an *ex vivo* expanded cell therapy product developed for the prevention of severe and/or prolonged SARS-CoV-2 infection early after allogeneic hematopoietic stem cell transplant (HSCT). This therapy aims to provide antiviral immune reconstitution in immunocompromised patients who are at high risk for severe COVID-19 due to their inability to mount an effective immune response post-transplant and prior to vaccine eligibility. The product is currently being evaluated in a Phase I dose escalation trial (NCT05141058).

Targets

SARS-CoV-2 spikepMHC (Peptide-MHC complex family)SARS-CoV-2 N protein MHC-I epitopes (SARS-CoV-2 nucleocapsid protein MHC class I epitopes)SARS-CoV-2 open reading frame 3a-derived peptides presented on major histocompatibility complex

Beyond the preview

Go deeper on donor-derived SARS-CoV-2-specific T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donor-derived SARS-CoV-2-specific T cells.

Explore the full profile